Introduction
Mammalian adipose tissue serves numerous functions for the organism, including insulation, thermogenesis and the production of regulatory hormones. However, most central to the adipocyte is its ability to store nutrients in an ef®cient and compact form, and to mobilize such energy stores in times of need. These include starvation, as well as other forms of metabolic stress. Although adipocytes have the capacity to extract both lipid and sugars from the circulation, the latter is perhaps more closely regulated and de®nes the ultimate rate of storage. Thus, transport of glucose across the fat cell membrane is, under most conditions, rate limiting for sugar metabolism in the cell. The latter regulates not only generation of ATP by glucose oxidation, but provides the backbone for fatty acid synthesis and the three carbon chain required for the esteri®cation of fatty acids taken up from the bloodstream. Thus, regulation of glucose entry into the cell serves as a primary regulatory site for the control of both nutrient storage and mobilization. Most critical to the regulation of this process is the level of circulating insulin as well as glucose itself.
The understanding of the molecular mechanisms by which insulin regulates glucose transport has been a subject of intense research for over 50 y. In the early 1980s, work from both Cushman's and Kono's laboratories led to the formal formulation of the`translocation hypothesis' (for review see Birnbaum. 1 ) According to this model, glucose transport proteins exist in the basal state in the interior of the cell in a latent state. After interaction of insulin with the fat cell, there is a subsequent movement of glucose transport proteins to the cell surface, resulting in an increase both in the number of transporters on the cell surface and the rate of hexose uptake. Although not absolutely required by this model, it is the common belief that the change in number of surface transporters and not their speci®c activity accounts for most of the increase in glucose uptake after exposure of the cell to insulin. Subsequent investigations have con®rmed this model in many of its details, but failed to clearly elucidate both the traf®cking pathways taken by the transporter, as well as the precise signaling cascade which leads from insulin's interaction with its receptor terminating on accelerated movement of transporter to the plasma membrane. Signi®cant data exist supporting the idea that insulin primarily stimulates the rate of movement of glucose transporters from within the cell to the cell surface, with a smaller but appreciable slowing of the rate of transporter internalization. Nonetheless, the precise compartment in which the transporter resides in the basal state, as well as the route it follows to the cell membrane and back to its storage compartment remains controversial.
The molecular cloning of an`insulin-responsive' glucose transporter, now known as the GLUT4 isoform, provided signi®cant insights into the rather specialized mechanisms of adapting hexose metabolism to different purposes. 2 GLUT4 is expressed virtually exclusively in insulin-responsive tissues, most notably heart, skeletal muscle and the adipocyte, although more recently it has been identi®ed at lower levels in such tissues as central neurons. GLUT1, the more ubiquitous glucose transport protein, is expressed at substantially lower levels in classical insulin target tissues, and redistributes in response to insulin to the plasma membrane to a much lower extent than GLUT4. Thus, one problem which needs to be resolved in terms of the subcellular traf®cking of glucose transporters is the differential regulation of the two transporter isoforms.
Considerable information has accumulated in recent years concerning intracellular signal transduction pathways regulated by insulin. Insulin binding to its cell surface receptor stimulates the latter's tyrosine kinase activity, which phosphorylates key residues on several`docking proteins', of which the prototypes are a family of insulin receptor substrate proteins (IRS 1 ± 4). Assembly of a stable complex leads to the regulation, in most cases the activation of downstream signaling pathways. Recruited proteins include the p85 regulatory subunit of P3-kinase, which stimulates signaling pathways ultimately leading to AktaPKB, pp70 S6-kinase or 4EBP1aPHAS1 activation. Thus far, PI3-kinase represents the only protein for which it has been possible to establish a role in regulating anabolic metabolism. This conclusion is derived from experiments using pharmacological inhibitors of PI3-kinase, overexpression of constitutively active forms of PI3-kinase and expression of dominant-negative PI3-kinase constructs. Microinjection experiments involving an antibody neutralizing for the p110a catalytic subunit have con®rmed a role for this class Ia isoform in insulin's stimulation of GLUT4 translocation. 3 The establishment of PI3-kinase as a requisite intermediate in signaling from the insulin receptor to accelerated glucose transport has led to a search for signaling molecules linking PtdIns-3,4,5-P 3 to GLUT4 traf®cking. Of the signaling molecules recognized to bind the lipid products of PI3-kinase, those implicated in insulin signaling fall into two classes: (1) guanine nucleotide exchange protein for the Arf family of small GTP-binding proteins; and (2) protein kinases, primarily those with substrate speci®city for serine and threonine residues. One of the leading candidate mediators of the latter class is the PI3-kinase-dependent serineathreonine protein kinase AktaPKB.
AktaPKB as a mediator of insulin action
The serineathreonine kinase AktaPKB has been identi®ed as a critical intermediate in PI3-kinase's metabolic and anti-apoptotic effects. 4 Initially identi®ed as a proto-oncogene and by degenerative PCR, numerous studies now indicate that AktaPKB lies downstream of PI3-kinase on a linear signaling pathway. Three mammalian isoforms, products of distinct genes, have thus far been identi®ed. Although AktaPKB was originally thought to be stimulated allosterically following interaction with the lipid products of PI3-kinase, it is now believed that phosphorylation represents a more important activating event. The current model for activation of AktaPKB is that polyphosphinositides bind directly to the PH domain of the kinase, resulting in an uncovering of phosphorylation sites, coupled with direct activation of upstream phosphoinositide-dependent kinases (PDKs) which phosphorylate AktaPKB. Phosphorylation on two regulatory residues, S473 and T308 for Akt1, is critical for complete AktaPKB activation. 4 Evidence supporting a role for AktaPKB in insulin's regulation of glucose metabolism is substantial. Insulin activates AktaPKB via PI3-kinase-dependent phosphorylation in skeletal muscle, 5 adipose tissue, 6 and tissue-culture systems, including the insulinresponsive adipocyte line, 3T3-L1. 7 Expression of constitutively active forms of AktaPKB, using either stable or inducible expression systems, stimulates glucose uptake and GLUT4 translocation. 8 AktaPKB also mimics insulin's effects on the intracellular traf®cking of another protein, the insulin-responsive aminopeptidase IRAP. Insulin increases cell surface IRAP primarily by stimulating exocytosis, with minimal effects on endocytosis. We have shown that expression of the active forms of AktaPKB mimics these effects of insulin, effecting IRAP translocation by preferentially stimulating its exocytosis. 9 
Speci®city in insulin signaling
One of the most impressive aspects of the regulation of metabolism by insulin is its remarkable speci®city. This phenomenon can be viewed in two different contexts: insulin activates glucose transport to a signi®cant extent only in appropriate target tissues, and only insulin (and IGF-1), but not other peptide growth factors, stimulates anabolic metabolism in muscle and adipose tissue. Both types of speci®city are critical to maintaining the normal physiological control of sugar and fat metabolism. In regard to the ®rst aspect of insulin speci®city, the cloning of cDNAs encoding GLUT4 suggested a plausible mechanism for tissuespeci®city in insulin action, ie its dependency on the expression of GLUT4. Nonetheless, this appears not to be the case, as overexpression of GLUT4 in nonresponsive tissues, even in the presence of adequate insulin receptors, is not suf®cient to confer insulinstimulatable glucose transport typical of a fat cell. 10 Whether tissue-speci®c signalling or traf®cking events or both contribute to the development of insulinresponsiveness in muscle and adipose tissue is unclear.
Insulin's unique effects on glucose uptake and GLUT4 translocation are in stark contrast to the effects of other mitogenic agonists. Although other growth factors activate remarkably similar signalling cascades in 3T3-L1 adipocytes, most are incapable of stimulating glucose uptake or GLUT4 translocation. The conventional explanation of this seeming contradiction relies on invocation of the subcellular compartmentalization of intracellular signaling pathways. Studies with AktaPKB suggest an alternative or perhaps complementary explanation to the selective responsiveness of certain tissues to insulin, but not to other growth factors. We have found that insulin but not platelet-derived growth factor (PDGF) activates both AktaPKB isoforms 1 and 2 in 3T3-L1 adipocytes as determined using four different methodologies. 11 First, phospho-speci®c antibodies. Second, an isoform-speci®c anti-Akt2 antibody detected an insulin, but not PDGF, induced retardation in electrophoretic mobility. Third, insulin, but not PDGF augmented the kinase activity of an epitopetagged form of Akt2. And fourth, the endogenous AktaPHB substrate glycogen synthase kinase 3b (GSK3b) was phosphorylated in vivo in response to insulin, but not to PDGF. Other signalling molecules were activated comparably by both agonists in this differentiated tissue, including the upstream PI3-kinase and its downstream targets pp70 S6-kinase and PHAS1. Moreover, insulin's ability to activate AktaPKB was adipocyte-speci®c, since PDGF was a potent stimulator of AktaPKB phosphorylation, electrophoretic retardation and kinase activity, as well as GSK3b phosphorylation, in pre-adipocyte 3T3-L1 ®broblasts analyzed just prior to differentiation.
The unique ability of insulin to activate AktaPKB in 3T3-L1 adipocytes suggests an important question: does PDGF stimulate PI3-kinase in cultured adipocytes? In the single report which addresses this issue by measuring in vivo generation of PtdIns-3,4,5-P 3 , insulin was much more potent than PDGF. 12 However, both hormones activate PI3-kinase as measured in the immune complex with equivalent ef®ciency.
11
In addition, at least one downstream PI3-kinasedependent signaling pathway, that leading to the activation of pp70 S6 kinase, is stimulated by PDGF in 3T3-L1 adipocytes, suggesting the production of phosphoinositides in vivo.
11 Recently, Oatey et al fused the pleckstrin homology (PH) domain of either the ADP-ribosylation factor nucleotide-binding-site opener (ARNO) or the general receptor for 3-phosphoinositides (GRP-1) to green¯uorescent protein (GFP) and expressed the chimeric protein in 3T3-L1 adipocytes. These PH domains have high af®nity and speci®city for binding to PtdIns-3,4,5-P 3 . Thus, the redistribution of GFP to a membrane structure has been taken as an indication of accumulation of PtdIns-3,4,5-P 3 in that compartment. Insulin signi®cantly stimulated the movement of the chimeric protein from the cytoplasm to the plasma membrane, whereas PDGF was a very weak agonist in this regard. 13 These data suggest that PtdIns-3,4,5-P 3 does not accumulate to a signi®cant extent in adipocytes exposed to PDGF.
Ceramide treatment as an in vitro model of insulin resistance
Insulin resistance has been de®ned as the inability of maximal concentrations of the hormone to appropriately stimulate glucose disposal or suppress glucose production. For the most part, a blunted response in skeletal muscle accounts for most of the defect in glucose uptake. 14 However, there is substantial evidence that perturbations of fat cell metabolism can alter insulin-stimulated glucose disposal in vivo to an extent disproportionate to the mass of adipose tissue. 15 This has been taken as an indication of a`long-range' effect of the adipose cell. The mechanism, for this is poorly understood, although a number of factors secreted from adipocytes have been suggested as candidate regulatory molecules. Insulin resistance represents a major component of type II diabetes mellitus. Although there still exists controversy as to whether insulin resistance or disordered insulin secretion is primary in the etiology of type II diabetes, there is general agreement that the peripheral component is critical to the maintenance of hyperglycemia and other systemic manifestations of the disease. This has been dramatically illustrated by the success of the thiazolidinediones, whose mechanism of action is to potentiate insulin action.
Studies with the sphingomyelin derivative ceramide suggest one plausible mechanism for the development of insulin-resistance. Short-chain ceramide analogs antagonize insulin's regulation of both glucose uptake and apoptosis, and the mechanism in both cases is thought to involve antagonism of the acitvation of AktaPKB. 16, 17 The speci®c site of modulation has been localized to between activation of PI3-kinase and subsequent stimulation of AktaPKB. The short chain analog C2-ceramide inhibits insulin-stimulated AktaPKB phosphorylation on both regulatory residues and reduces AktaPKB activity as assayed in the immune complex. 17 C2-ceramide also blocks the insulin-induced mobility shift in AktaPKB as resolved by SDS polyacrylamide gel electrophoresis. Lastly, C2-ceramide's inhibitory actions on glucose transport and cell survival are bypassed by overexpression of a constitutively active form of AktaPKB. Ceramide appears not to work by inhibiting the tyrosine phosphorylation of IRS-1, as the lipid also antagonizes PDGF-stimulated AktaPKB phosphorylation, an event which occurs independent of IRS-1. 17 Ceramide's inhibition of AktaPKB and the activation of glucose transport suggest a common mechanism for the onset of both the insulin-resistance defect in skeletal muscle as well as the beta-cell apoptosis observed in the pancreas of type II diabetics. Abnormally elevated ceramide production in these tissues could, by inhibiting Akt activity, account for both of these pathological defects. Interestingly, two circulating factors hypothesized to mediate insulin resistance, TNF and free fatty acids, promote intracellular ceramide production. 18, 19 Free fatty acids can also trigger pancreatic beta-cell apoptosis by a mechanism which is prevented by a ceramide synthase inhibitor. 19 Intracellular ceramide concentrations in the skeletal muscle from obese, diabetic rats are elevated, consistent with their contributing to insulin-resistance. 20 Finally, we recently observed that ceramide inhibits insulin-stimulated glucose uptake in isolated soleus muscle (Yin and Birnbaum, unpublished data).
The discovery of AktaPKB as an insulin-responsive kinase has contributed much to our understanding of insulin signal transduction mechanisms. Nonetheless, several questions persist before a complete understanding of AktaPKB's role in insulin action is achieved. The necessity of AktaPKB activation for insulin-stimulated glucose uptake and GLUT4 translocation is yet to be resolved, and the downstream effectors of AktaPKB action have not been completely elucidated. 21 Furthermore, the molecular mechanisms that account for the uncoupling of PDGFstimulated AktaPKB activation require delineation. Despite these and other missing pieces of information, the preponderance of data indicates that AktaPKB is a multi-potent participant in numerous insulinmediated responses.
